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Abstract
Impaired hemostasis coexists with accelerated atherosclerosis in patients with chronic kidney disease (CKD). The elevated
frequency of atherothrombotic events has been associated with endothelial dysfunction. The relative contribution of the
uremic state and the impact of the renal replacement therapies have been often disregarded. Plasma markers of endothelial
activation and damage were evaluated in three groups of patients with CKD: under conservative treatment (predialysis), on
hemodialysis, and on peritoneal dialysis. Activation of p38 MAPK and the transcription factor NFkB was assessed in
endothelial cell (EC) cultures exposed to pooled sera from each group of patients. Most of the markers evaluated (VCAM-1,
ICAM-1, VWF, circulating endothelial cells) were significantly higher in CDK patients than in controls, being significantly
more increased in the group of peritoneal dialysis patients. These results correlated with the activation of both p38 MAPK
and NFkB in EC cells exposed to the same sera samples, and also to the peritoneal dialysis fluids. Hemodialysis did not
further contribute to the endothelial damage induced by the uremic state observed in predialysis patients, probably due to
the improved biocompatibility of the hemodialysis technique in recent years, resulting in lower cellular activation. However,
peritoneal dialysis seemed to exert a significant proinflammatory effect on the endothelium that could be related to the
high glucose concentrations and glucose degradation products present in the dialysis fluid. Although peritoneal dialysis has
been traditionally considered a more physiological technique, our results raise some doubts with respect to inflammation
and EC damage.
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Introduction
Patients with chronic kidney disease (CKD) suffer from complex
hemostasis disorders. Both a bleeding tendency and an increased
risk of accelerated atherosclerosis, with a high incidence of
cardiovascular death, have been described to coexist [1].
Moreover, these patients are known to be exposed to a chronic
proinflammatory state and oxidative stress, leading to endothelial
cell dysfunction. In hemodialyzed patients, humoral factors such as
uremic toxics accumulated in plasma and cytokines released by
cellular activation are involved in the development of these
pathological processes [2,3,4,5].
The vascular endothelium has been recognized as a complex
endocrine organ that regulates many physiological functions
such as vascular tone, vascular smooth muscle cell growth and
migration, vascular permeability to solutes and blood cells, and
regulation of hemostasis, among others [6]. The endothelium is
able to adapt to pathophysiological challenges. However,
depending on the nature and intensity of the stimuli, the
endothelium may become dysfunctional. In this regard, there is
clinical [7,8,9] and experimental evidence of endothelial
activation and damage in uremia [10,11,12,13]. In patients
with CKD, the progression of atherothrombosis is accelerated
[14], causing early cardiovascular complications [15]. In this
regard, mortality from cardiovascular disease is nearly tenfold
higher in patients with end-stage renal disease (ESRD) on
dialysis than in the general population (US Renal Data System,
USRDS 2009 Annual Data Report). This clinical situation
cannot be fully explained by an increased prevalence of
traditional cardiovascular risk factors such as hypertension,
diabetes, hyperlipidemia or smoking, in ESRD [16]. Similarly,
an enhanced cardiovascular risk has been reported in patients
with CKD not on dialysis [17].
Using endothelial cells in culture, our group has previously
characterized the endothelial activation and damage occurring in
association with CKD. When exposed to growth media containing
sera from patients on hemodialysis, cells showed morphological
alterations [13], increased proliferation [13], signs of inflammation
with no evidence of apoptosis [12,13], and an increased
thrombogenicity of the generated extracellular matrix [18,11]. A
more recent proteomic approach revealed that there are changes
in the expression of some molecules related to inflammation, such
as HMGB1 and aldose reductase, and to oxidative stress, such as
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superoxide dismutase and glutathione peroxidase. These changes
were correlated with the activation of the transcription factor
NFkB [19].
Most of the studies on the endothelial damage in CKD patients
have been conducted in patients undergoing hemodialysis
treatment. In the present study, we have investigated the relative
contribution of uremia and renal replacement therapies (RRT),
hemodialysis and peritoneal dialysis, to the development of
endothelial damage in patients with CKD. We applied two
different approaches: ex vivo analysis of plasma markers of
endothelial activation and damage, and in vitro evaluation of the
signaling mechanisms involved.
Results
Main demographic characteristics and biochemical
parameters of the patients included in the study
The present studies were carried out in four different groups:
i) 15 healthy donors (control group), ii) 11 patients under
conservative treatment (PreD group), iii) 15 patients undergo-
ing hemodialysis (HD group), and iv) 9 patients under
peritoneal dialysis (PD group). Patients with diabetes and/or
dyslipidemia, and smokers were excluded. The main demo-
graphic characteristics and biochemical parameters are de-
tailed in Table 1.
Levels of endothelial damage markers are increased in
dialyzed patients, specially in those under peritoneal
dialysis
Plasma sVCAM-1, sICAM-1, and VWF increased significantly
in the three groups of patients (p,0.01, p,0.05, and p,0.01 vs.
control). Values of sPECAM-1, sE-SELECTIN, and sP-SELEC-
TIN were higher in PreD and PD groups. However, ADAMTS-13
activity was within the normal range (table 2).
Circulating EC, identified as CD452/CD146+/CD31+/
CD133+ by flow cytometry, were above the control values
(,100 CEC/mL) in all CKD groups, being significantly higher in
the PD group with respect to the rest of groups (see table 2).
Uremic media promotes activation of the p38 MAPK and
NFkB p65/ReIA signaling pathways
Changes in the activation state of both p38 MAPK and NFkB,
expressed as the relative extent of the phosphorylated target
protein, are shown in figure 1 and 2, respectively. Two different
techniques were applied: a phosphospecific antibody cell-based
ELISA, which is faster but probably less sensitive, and immuno-
blotting as a reference method.
In relation to p38 MAPK, a statistically significant increase in
the levels of the phosphorylated protein was observed in cells
exposed to sera from the PD group, after 1 and 15 min (increases
of 71.462.5% and 28.461.9% vs. control, respectively, both
Table 1. Main demographic characteristics and biochemical parameters.
Control (n = 15) PreD (n = 11) HD (n = 15) PD (n = 9)
Age, yr, mean6SD 42.3610.0 62.4611.2 51.2614.5 61.4620.4
Gender male/female 7/8 10/1 8/7 5/4
Mean glomerular filtration rate (ml/min/1.73 m26SD) – 19.067.8 – –
Residual renal function (ml/min) mean6SD – – 0 5.364.8
Mean time on dialysis, months6SD – – 55.9670.5 16.166.2
Serum Albumin (g/dl) mean6SD 4.260.3 4.560.2 4.160.3 3.760.2
Hemoglobin (g/dl) mean6SD 12.261.1 12.861.8 11.861.3 12.161.1
Leukocytes (109/l) mean6SD 7.561.2 7.661.1 6.2161.96 7.061.6
Causes of CKD n (%)
glomerulonephritis 3 (27.3%) 4 (26.7%) 0
interstitial nephropathy 2 (18.2%) 0 0
renal hypoplasia 1 (0.9%) 0 0
polycystic kidney disease 0 3 (20.0% 2 (22.2%)
systemic lupus erythematosus 0 1 (0.7%) 0
hemolytic uremic syndrome 0 1 (0.7%) 0
bilateral nephrectomy 0 1 (0.7%) 0
obstructive kidney disease 0 1 (0.7%) 0
nephrosclerosis 0 0 2 (22.2%)
unknown 4 (36.4%) 4 (26.7%) 5 (55.6%)
Hypertension n (%) 0 9 (81.8%) 15 (100%) 4 (44.4%)
Use of statins n (%) 0 7 (63.6%) 5 (33.3%) 8 (88.9%)
Use of vitamin D n (%) 0 8 (72.7%) 5 (33.3%) 9 (100%)
Use of erythropoietin n (%) 0 3 (27.3%) 12 (80.0%) 8 (88.9%)
Use of inhibitors of the Renin-Angiotensin System 0 5 (45.5%) 1 (6.7%) 4 (44.4%)
doi:10.1371/journal.pone.0043374.t001
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p,0.05, n = 6). Levels of p38 MAPK activation in the PreD and
HD groups were similar to those observed in the control group.
Increases of 7.460.3% and 4.260.01% in response to PreD and
HD sera, respectively, were detected after 1 min of activation, and
no significant variations were detected after 15 min. Activation of
p38 MAPK in cells exposed to the conditions under study was
confirmed by immunoblotting (see figure 1). Although activation of
p38 MAPK was observed in the C, PreD and HD groups, specially
at 15 min, it was mild. Phosphorylation of p38 MAPK increased
progressively when cells were exposed to sera from the PD group
from 15 to 60 min, being really significant at 60 min (increase of
the mean intensity from 0 to 60%, p,0.001).
Additionally, NFkB p65/ReIA showed a higher ratio of
phosphorylation when EC were exposed to the sera of the three
groups of uremic patients when compared to the control group.
The most notable changes were observed when EC were
incubated with the sera from PD patients at 1 and 15 min of
exposure (increases of NFkB activation of 6562.9% and 8562.6%
vs. control, respectively, both p,0.05, n = 6). Although not
statistically significant, there was also an activating effect of the
HD sera (increases of 1964.5% and 2763.8% at 1 and 15 min of
exposure, n = 6). Sera from PreD patients also caused a significant
activation of NFkB at 15 min (4662.1%, p,0.05 vs. control,
n = 6).
Western-blot analysis of phospho-IkB showed that this tran-
scription factor was equally activated in cells exposed to the sera
from the three groups of patients and it was not detected in cells
exposed to control sera (see figure 2). Mean intensity of
phosphorylation in cells exposed to sera from the three different
groups of uremic patients was maximal at 15 min of exposure
(p,0.001) and was sustained till 30 min in the HD group
(p,0.001).
Effect of the glucose and its degradation products on
endothelial damage and inflammation
The results obtained throughout the present study led us to
explore the potential causes of endothelial activation in the group
of peritoneal dialysis patients. Glucose degradation products
(GDP) present in heat-sterilized dialysis solutions are thought to
contribute to cellular dysfunction and membrane damage during
peritoneal dialysis. Therefore, we examined the impact of
conventional and low GDP peritoneal dialysis solutions with
different concentrations of glucose (1.5%, 2.3%, and 4.25%), and
Icodextrin, on the activating state of the signaling molecules
explored.
Phosphorylation of both p38 MAPK and NFkB p65/ReIA,
expressed as the phosphorylation signal measured at 450 nm and
corrected by the relative number of cells measured at 595 nm, was
really significant in cells exposed to all the solutions tested for
15 min (see figure 3).
When compared to the basal condition, phosphorylation levels
of p38 MAPK increased 8562.5% (p,0.01) in response to the PD
sera, and 4462.8% (p,0.05) in response to icodextrin. When cells
were exposed to the 1.5%, 2.3% and 4.25% c-PDS, phosphor-
ylation of p38 MAPK was more notable and occurred in a
concentration-dependent manner, increasing in 7662.3%,
8763.4% and 12765.6% (all p,0.01). The activating effect of
the low GDP-PDS, although significant vs. the basal state and in a
concentration dependent manner, was always below that induced
by the PD pool of sera (increases of phosphorylation of 961.9%,
1360.9% and 2862.5%, p,0.05, in response to the 1.5%, 2.3%
and 4.25% GDP-PDS vs. the basal state).
In relation to the the NFkB, results were similar to those
observed for p38 MAPK. Activation vs. the basal state increased to
11463.0% with PD sera, 5363.2%, 12563.1% and 13464.0%
in response to the 1.5%, 2.3% and 4.25% c-PDS, and 3561.8%,
5461.7% and 3460.9% in response to the 1.5%, 2.3% and
4.25% GDP-PDS. The effect of Icodextrin was much more intense
on the phosphorylation of the transcription factor NFkB, even
above all the conditions studied (increase of 17864.9% vs. the
basal state).
Discussion
The present study was focused to discern the contribution of
uremia and the RRT to the development of endothelial activation
and damage. The ex vivo and in vitro approaches applied revealed
that uremia per se causes a proinflammatory state on the
endothelium, as derived from results in pre-dialysis patients. The
hemodialysis technique with the current advances (generalized use
of biocompatible membranes and ultrapure water, among others)
did not exhibit a damaging effect on the endothelium additionally
to that observed in patients with advanced CKD managed
conservatively. Interestingly, peritoneal dialysis was the most
proinflammatory condition, as demonstrated by a higher presence
of soluble markers of endothelial activation and damage in plasma,
and a more intense activation of both p38 MAPK and NFkB
signaling pathways in cultured endothelial cells. These effects
Table 2. Levels of soluble biomarkers of endothelial activation and damage measured in plasma.
Control (n = 15) Predialysis (n = 11) Hemodialysis (n = 15) Peritoneal dialysis (n = 9)
sVCAM-1 (ng/ml) 816.9664.2 1496.06190.4** 1427.56191.0** 1781.46254.1**
sICAM-1 (ng/ml) 130.8614.0 281.7615.6* 296.6620.4* 376.2635.3*
sPECAM-1(ng/ml) 145.3621.0 226.7640.0 155.1615.3 251.1640.1*
sE-selectin (ng/ml) 88.8610.3 109.5615.8 70.767.7 86.1611.0
sP-selectin (ng/ml) 244.1622.2 347.6637.3* 225.3623.6 331.8635.4*
VWF (%) 83.6611.3 153.4611.4** 210.8631.9** 173.2615.7**
CEC/ml ,100 263.3675.3 155.6652.2 471.06119.2*
ADAMTS-13 (%) 103.0620.0 104.766.3 100.166.6 93.265.1
Data are means6S.E.M.
*p,0.05 and
**p,0.01 vs. the control group.
doi:10.1371/journal.pone.0043374.t002
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could be attributed, at least in part, to the glucose and its
degradation products present in the PD dialysis fluids.
Endothelial activation and damage could be the earliest
indicator of subclinical cardiovascular disease. In the laboratory,
measurement of plasma levels of different molecules and/or other
elements, either discharged or up-regulated in an activated
endothelium, could be useful to assess endothelial damage and
activation [20,21]. Considering that to date there is no universal
marker of endothelial damage, we have evaluated different
indicators. Soluble adhesion receptors were evaluated by a
multiplex system and showed significant activation of the
endothelium in all uremic patients, being more notable in the
PreD and PD groups. In relation to VWF plasma levels, our
present data is consistent with previous observations in hemodia-
lyzed patients [7] being significantly higher in all the uremic
patients than in controls. However, the short range in which values
are included might explain the lack of differences found between
the studied groups. Levels of circulating endothelial cells (CEC)
have been described to correlate well with VWF plasma levels
[22]. There is previous evidence generated in HD patients of
increased CEC and their association with future cardiovascular
events [10,23]. In our present study, blood CEC counts were
higher in all the uremic patients when compared to the control
group, especially in the group of peritoneal dialysis.
The analysis of plasma markers of endothelial damage indicates
that the toxic environment of uremia causes inflammation on the
endothelium, as observed in the non dialyzed CKD patients. This
inflammatory effect is also seen in patients under both types of
Figure 1. Effect of uremic media on the activation of p38MAPK signaling pathway. A. Ratios of phosphorylated p38 MAPK relative to the
total protein, obtained in EC after 1 and 15 min of incubation with pooled sera from control donors (C), and predialysis (PreD), hemodialysis (HD), and
peritoneal dialysis (PD) groups of patients. Data are corrected for cell number and are represented as mean6SEM (n = 6); *p,0.05 when compared
with the other groups. B. EC were incubated at different time points with pooled sera from the same groups (C, PreD, HD, and PD, as indicated), and
then assayed for phospho-p38 MAPK in cytosolic fractions by Western blot analysis. Images are representative of 6 different experiments and bar
diagrams represent the mean intensity of phosphorylation (*p,0.05, **p,0.001).
doi:10.1371/journal.pone.0043374.g001
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RRT. From the results obtained, it can be predicted that PD
exhibits the most deleterious effect on the endothelium and,
interestingly, current HD techniques have diminished the harmful
effect previously ascribed to this treatment.
Previous studies by our group and others were mostly
performed in hemodialyzed patients. Results have demonstrated
the existence of endothelial activation and damage in CKD both in
vivo and in vitro. Plasma levels of endothelium-derived proteins [7],
some of them vasoactive factors, are increased in these patients
[24]. Endothelium-dependent vasodilation, the gold-standard
method to assess endothelial function in vivo, is also decreased in
these patients [25]. Exposure of cultured EC to sera from
hemodialyzed patients accelerates cell cycle and proliferation,
with a more prothrombotic extracellular matrix and a proin-
flammatory phenotype with a higher expression of cell adhesion
molecules [13,12], which represents one of the earliest patholog-
ical changes in immune and inflammatory diseases such as
atherosclerosis [26]. Moreover, a proteomic characterization of
these changes demonstrated a differential expression of proteins
associated with inflammation and oxidative stress in cells exposed
to the uremic condition, related to the NFkB signaling pathway
[19]. In fact, exposure of endothelial cells in culture to sera from
hemodialyzed patients induces activation of p38 MAPK [12] and
of NFkB [19]. In hemodialyzed patients there is presence of the
uremic toxics but also of those components released by blood cells
that become activated by the procedure itself. However, results
from the present study indicate that there is not an additional
deleterious effect of hemodialysis over that observed in the
predialysis condition. Probably, the generalized use of more
biocompatible dialysis membranes and ultrapure water, among
Figure 2. Effect of uremic media on the activation of NFkB p65/ReIA signaling pathway. A. Ratios of phosphorylated NFkB p65/ReIA
relative to the total protein, obtained in EC after 1 and 15 min of incubation with pooled sera from control donors (C), and predialysis (PreD),
hemodialysis (HD), and peritoneal dialysis (PD) groups of patients. Data are corrected for cell number and are represented as mean6SEM (n = 6);
*p,0.05 when compared with the other groups; #p,0.05 when compared with the control group. B. EC pretreated (for 30 min at 37uC) with N-
acetyl-leucyl-leucyl-norleucinal (ALLN, 50 mg/ml) were incubated at different time points with pooled sera from the same groups (C, PreD, HD, and
PD, as indicated), and then assayed for phospho-IkBa in cytosolic fractions by Western blot analysis. Images are representative of 6 different
experiments and bar diagrams represent the mean intensity of phosphorylation (*p,0.05, **p,0.001).
doi:10.1371/journal.pone.0043374.g002
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other advances, has reduced blood cell stress with less contribution
of proinflammatory cytokines. Interestingly, PreD patients showed
a more significant inflammatory state than HD patients. These
results are not fully in agreement with those by Merino et al. [27].
In their study, PD seems to exhibit a lower damaging condition on
the endothelium than HD and predialysis. Differences between
both studies may be due to the different experimental approaches
applied but especially to the fact that in our study patients with
CKD did not have evidence of previous cardiovascular disease and
other known cardiovascular risk factors.
The present study provides the first evidence that sera from PD
patients have a greater activating effect on p38 MAPK and NFkB,
two intracellular key markers of inflammation and cell damage.
The p38 MAPK protein kinases affect a variety of intracellular
responses, with well-recognized roles in inflammation, cell-cycle
regulation, cell death, development, differentiation, senescence
and tumorigenesis [28]. NFkB seems to act by regulating the
expression of several genes involved in tumorigenesis, including
anti-apoptotic proteins, cyclooxygenase-2, matrix metalloprotei-
nase-9, genes encoding adhesion molecules, chemokines, and
inflammatory cytokines; and cell cycle regulatory genes [29].
Therefore, both p38 MAPK and NFkB participate in the
proinflammatory responses and exhibit a clear role in the
development of inflammatory and immunological diseases.
According to the USRDS 2011 Annual Data Report, mortality
rates of dialyzed patients have declined in the last years probably
reflecting changes in catheter utilization, improved cardiovascular
disease care, and changes in infectious complications. However,
cardiovascular disease is still the major cause of the limited life
expectancy in patients on substitutive therapies [30,31].
Patients under peritoneal dialysis are often hypertensive and
sometimes volume overloaded [32], which is related to endothelial
damage in PD patients [33]. Glucose is absorbed to a large extent
from the dialysate, and conventional PD results in an almost
unique metabolic situation involving continuous 24-hour absorp-
tion of glucose. One common and important side effect of this
treatment is weight gain and accumulation of body fat stores
[34,35]. These patients develop hyperlipidemia, with high levels of
low-density lipoprotein and triglycerides. Advanced glycation end-
products (AGEs), which are believed to promote atherosclerosis
through interaction with endothelial receptors [36], are commonly
accumulated in CKD patients due to decreased renal clearance,
could be overproduced in PD patients due to the high exposure to
glucose and glucose degradation products (GDP). Bioincompat-
ibility of conventional glucose-based peritoneal dialysis fluids
(PDF) has been partially attributed to the presence of GDP
generated during heat sterilization of PDF [37,38], which are
thought to contribute to cellular dysfunction and membrane
damage during peritoneal dialysis [39,35,40]. In accordance with
these previous results, our present study shows that the glucose
load and the presence of GDP could play a role in the
development of endothelial damage among these patients.
Icodextrin is a colloid osmotic agent, derived from maltodextrin,
used as aqueous solution for peritoneal dialysis. The osmotic
activity of icodextrin keeps the solution inside the peritoneum for
10 to 16 hours without being significantly metabolized. Due to its
chemical characteristics, Icodextrin reduces the burden of glucose
overexposure. From this perspective, the activating effect of
Icodextrin on the transcription factor (and to a lesser extent on the
inflammation-dependent protein p38 MAPK) is difficult to
explain. It can however not be excluded that the pH of the
Icodextrin solution could exert a damaging effect on the
endothelium in our in vitro studies.
From our present results it can be concluded that there is
endothelial activation and damage associated with CKD, as
demonstrated by the increased presence of plasma markers and by
the in vitro studies in cultured endothelial cells. The uremic state
seems to be a major cause of endothelial damage, probably
through the activation of transcription factors, such as NFkB,
which are related to inflammation. However, while improved
hemodialysis procedures do not seem to have an additional
deleterious effect, our different experimental approaches applied
indicate that peritoneal dialysis seems to exert a more intense
proinflamatory action on the endothelium that could be due, at
least in part, to the increased glucose load. Studies to elucidate the




Written informed consent was obtained for blood utilization
from every healthy donor and patient included in the study. The
study was approved by the ethical committee of the Hospital
Clinic (2011/6238) and was carried out according to the principles
of the Declaration of Helsinki.
Experimental Design
We have applied both an ex vivo approach to analyze the
presence of soluble plasma biomarkers of endothelial activation
and damage and an in vitro approach to explore the activation of
Figure 3. Effect of different peritoneal dialysis fluids on the
activation of p38MAPK and NFkB p65/ReIA signaling path-
ways. Levels of phosphorylated p38 MAPK (A) and NFkB p65/ReIA (B),
represented as phospho-p38 MAPK and phospho-NFkB signal at 450/
595 nm, were evaluated in EC after 15 min of incubation with the
pooled sera from the PD group and with the different peritoneal dialysis
solutions: icodextrin (Ico) (7.5%), conventional (c-PDS) and low GDP
(Low GDP-PDS) peritoneal dialysis solutions (at the concentrations of
glucose of 1.5%, 2.3%, and 4.25%). Data were plotted after correction
for cell number and are represented as mean6SEM (n = 6); *p,0.05 and
**p,0.01 when compared with basal levels of phosphorylation.
doi:10.1371/journal.pone.0043374.g003
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key signaling pathways related to inflammation in cultured
endothelial cells exposed to sera from uremic patients.
In order to investigate the relative contribution of uremia and
substitutive therapies, studies were carried out in four different
groups: i) 15 healthy donors (control group), ii) 11 patients under
conservative treatment (PreD group), iii) 15 patients undergoing
hemodialysis (HD group), and iv) 9 patients under peritoneal
dialysis (PD group). Patients with diabetes and/or dyslipidemia,
and smokers were excluded.
In subsequent experiments, endothelial cells were exposed to
conventional and low GDP peritoneal dialysis solutions with
different concentrations of glucose (1.5%, 2.3%, and 4.25%), and
to Icodextrin (7.5%), to explore their effect on the signaling
pathways under study.
The present study has some limitations, mainly due to its nature:
this is a cross-sectional observational study in which the sample
population is small. However, the ex vivo measurements were
performed in duplicate and confirmed by different techniques.
The in vitro studies were performed in triplicate, using pooled sera
from each group of patients to minimize variations, and also
confirmed by two different experimental approaches.
Patients and sample collection
PreD samples were obtained from 11 (7 men and 4 women) non
dialyzed patients with CKD (stage IV and V), age 62.4611.2
(mean6SD), glomerular filtration rate 19.067.8 ml/min/
1.73 m2, with glomerulonephritis (3), interstitial nephropathy (3),
renal hypoplasia (1), and unknown (4). HD group consisted of 8
men and 7 women, age 55.2614.5, residual renal function 0 ml/
min, and time on dialysis 55.9670.5 months. Causes of renal
failure in these patients were glomerulonephritis (4), polycystic
kidney disease (3), systemic lupus erythematosus (1), hemolytic
uremic syndrome (1), bilateral nephrectomy (1), obstructive kidney
disease (1), and unknown (4). All HD patients were dialyzed with
biocompatible membranes, ultrapure water, for $4 hours, with a
Kt/V$1.3. Samples were always obtained before the HD session.
In the PD group, 5 men and 4 women with polycystic kidney
disease (2), nephrosclerosis (2), and unknown (5) were included,
age 61.4620.4, residual renal function 5.364.8 ml/min, and time
on dialysis 16.166.2 months. PD patients only used biocompatible
solutions with low levels of GDP: 5 BicaveraTM (Fresenius, Spain),
2 PhysionealTM (Baxter, Spain), 2 Gambrosol TrioTM (Gambro,
Spain) and 3 patients used ExtranealTM (Baxter, Spain). The
glucose concentration used or the indication for icodextrin
(ExtranealTM) was based on the patient’s hydration status and
peritoneal transport characteristics. None of the PD patients had
had a peritonitis episode in the previous 2 months. See table 1 for
patients data.
Diabetic patients or patients with dyslipidemia and/or previous
cardiovascular disease and smokers were excluded. Most of the
patients had no vascular disease as a cause of CKD. Samples from
healthy donors were obtained as controls (n = 15, 7 male and 8
women, mean age 61.4620.4).
Plasma and sera samples were obtained from each patient by
centrifugation of citrated blood (8006g, 15 min) and non
anticoagulated blood (30006g, 15 min), respectively, and stored
at 220uC until use.
Analysis of soluble markers of endothelial activation and
damage
Plasma levels of VCAM-1, ICAM-1, PECAM-1, E-SELECTIN
and P-SELECTIN were quantified by flow cytometry (Flowcyto-
mix, Bender MedSystems; LabClinics S.A, Barcelona, Spain). This
system employs capture antibodies coupled to fluorescent poly-
styrol beads of different sizes. A dual-laser flow cytometer
(FACScan, Becton-Dickinson, Mountain View, Ca, USA) identi-
fies the beads based upon their size and fluorescence intensity, and
then quantifies the amount of antigen by measuring fluorescence
emitted from Streptavidin-Phycoerythrin (PE) associated with a
biotinylated detector antibody.
Circulating EC were measured by the flow cytometry method,
in which whole blood was labelled with monoclonal antibodies
tagged with fluorochromes (anti-CD45-PerCP, anti-CD146-FITC,
anti-CD31-PE, anti-CD133-APC) (Chemicon Int, BD Pharmin-
gen, Miltenyi Biotech, Becton & Dickinson).
VWF was evaluated by ELISA (American Diagnostica, Grifols
SA, Barcelona, Spain). ADAMTS-13 activity was analyzed in
citrated plasma by a fluorescence resonance energy transfer assay
using a truncated synthetic 73-amino-acid VWF peptide as a
substrate (FRETS-VWF73 assay) [41].
Culture of human umbilical vein endothelial cells
Primary cultures of EC were isolated from human umbilical
cords veins, according to a previously described method [42], by
collagenase treatment (0.2% in phosphate buffered saline, PBS,
15 min, 37uC) (Boehringer Mannheim, Mannheim, Germany).
Cells were grown with culture medium (Mem 199; Gibco BRL,
Life Technologies, Scotland, UK) supplemented with 100 U/ml
penicillin, 50 mg/ml streptomycin and 20% pooled human serum.
EC were grown at 37uC in a 5% CO2 humidified incubator. The
culture medium was changed every 48 h. After the second
passage, EC were subcultured for 24 h on 0.1% gelatin-coated
96-well plates or on 0.1% gelatin-coated 6-well plates. Cells were
used before reaching confluency.
Activation of the p38 MAPK and NFkB signaling
pathways in endothelial cells
The activation of the p38 MAPK and NFkB p65/ReIA
signaling pathways was assessed in cultured EC by two methods:
a phosphospecific antibody cell-based ELISA, and immunoblot-
ting.
To assess activation of p38 MAPK and NFkB by the
phosphospecific antibody cell-based ELISA, endothelial cells were
seeded in 96-well plates. After 24 h, confluent cells were serum
starved during 4 h before experiments were performed by
replacing their growth media with media containing 2% pooled
human serum. This experimental procedure ensures basal levels of
protein activity. Cells were then incubated for 1, 5, and 15 min
with the 4 different pooled sera. The activation (phosphorylation)
was evaluated by the cellular activation of signaling ELISA
(CASE) kit superArray (SABiosciences, Tebu-bio Lab, Spain). The
kit includes a complete antibody-based detection system for
colorimetric quantification of the relative amount of phosphory-
lated protein and total target protein [43]. Detection of total and
phosphorylated protein expression was determined according to
the manufacturer’s protocol and the levels obtained were corrected
for cell number.
The activation of each of these signaling pathways was
confirmed by immunoblotting as a reference method. EC were
lysed with Laemmli buffer (125 mmol/l of Tris-HCl, 2% SDS, 5%
glycerol, and 0.003% bromophenol blue), sonicated for 15 seconds
to shear DNA and reduce viscosity, and heated to 90uC for 5 min.
Protein concentrations of the supernatants were determined using
Coomassie Plus (Pierce) as recommended by the manufacturer
[44]. Samples were resolved by using 8% SDS-PAGE and proteins
were transferred to nitrocellulose membranes, which were probed
with specific antibodies to p38 MAPK phosphorylated at Thr180
and Tyr182, and to phosphorylated IkB (Cell Signaling Technol-
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ogy Inc, Frankfurt, Germany). Considering that translocation of
NFkB to the nucleus is preceded by the phosphorylation and
degradation of IkB, we analyzed the phosphorylation of the IkB
protein in the presence of N-acetyl-leucyl-leucyl-norleucinal
(ALLN) which prevents its degradation by the 26S proteasome
[45]. Then, membranes were incubated with a peroxidase-
conjugated anti-rabbit immunoglobulin G and developed using
the chemiluminiscence technique. The presence of proteins was
confirmed using specific antibodies. Densitometric analysis was
performed to quantify the intensity of phosphorylation (ImageJ,
National Institutes of Health, Bethesda, Maryland, USA).
Effect of the peritoneal dialysis fluids on p38 MAPK and
NFkB signaling pathways
The effect of Icodextrin (Extraneal, Baxter, Spain), conventional
peritoneal dialysis solutions (Stay-Safe 1.5%, Stay-Safe 2.3%,
Stay-Safe 4.25% from Fresenius Medical Care, Spain), and low
GDP peritoneal dialysis solutions (BicaVera 1.5%, BicaVera 2.3%,
BicaVera 4.25% from Fresenius Medical Care, Spain) on the
activation of p38 MAPK and NFkB in cultured endothelial cells
was also assessed.
The amount of activated (phosphorylated) p38 MAPK and
NFkB p65/ReIA was quantified in cultured endothelial cells after
15 min of incubation by using the Cellular Activation of Signaling
ELISA (CASETM) kit superarray (SABiosciences, Tebu-bio Lab,
Spain).
Cell viability was assessed in cultures exposed to the solution
under study by the uptake of the vital dye Trypan blue (0.4% in
PBS), according to standardized protocols for cell culturing and
maintenance, and also by the MTT method. Cell viability was
never lower than 90%.
Statistics
Results are expressed as mean 6 standard error of the mean
(SEM) and as ratios of phosphorylated protein with respect to the
total protein values. Statistical analysis was performed with raw
data using the Student’s t-test for unpaired samples and ANOVA.
Results were considered statistically significant when p,0.05. The
SPSS statistical package 17.0.0 (SPSS Inc, Chicago, IL) was used
for all analyses.
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